D2 dissection for gastric cancer

Surgical Oncology

Volumn 6, Issue 4, 1998, Pages 215-225

  Lee, Jeffrey S ^a   Douglass Jr , Harold O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FLUOROURACIL; MITOMYCIN C; SEMUSTINE; UFT;

BALTIC STATES; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL AMERICA; DISSECTION; GASTRECTOMY; HUMAN; JAPAN; KOREA; LYMPH NODE; LYMPH NODE METASTASIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SEROSA; SOUTH AMERICA; STOMACH CANCER; STOMACH MUSCLE; TREATMENT OUTCOME; UNITED STATES;

GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM STAGING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0031403647     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(98)00009-7     Document Type: Review

References (55)

1. 1. Brennan M. and Karpeh M. Surgery for gastric cancer: the American view. Seminars in Oncology 1996, 23, 352-359.
2. 2. Parker S. L., Tong T., Bolden S. and Wingo P. A. Cancer statistics 1996. CA 1996, 46, 5-27.
3. 3. Jessup J. M., Posner M., Huberman M., LoCicero J., Stone M. and Steele G. Efficacy of multimodality therapy in gastric adenocarcinoma. Seminars in Surgical Oncology 1993, 9, 19-26.
4. 4. Parkin D. M., Laara E. and Muir C. S. Estimates of the world wide frequency of sixteen major cancers in 1980. Int. J. Cancer 1988, 41(2), 184.
5. 5. Borrmann, R. Geschwulste des magen und dudenums. In Handbuch der Spezieller Pathologischen Anatomie und Histologie, Vol. 4, p. 865 (eds Henke, F. and Lubarsch, O.) Springer, Berlin, 1926.
6. 6. Watanabe, H., Jass, J. R. and Sobin, L. H. Histologic typing of gastric and oesophageal tumors. In World Health Organization; International Histologic Classification of Tumors. Springer, Berlin, 1990.
7. 7. Broders, A. C. Carcinoma and other malignant lesions of the stomach: pathologic considerations. In Carcinoma and Other Malignant Lesions of the Stomach, p. 127 (eds Waltman, W., Gray, H. K. and Priestly, J. T.) W. B. Saunders, Philadelphia, 1942.
8. 8. Nagayo T. and Komagome T. Histologic studies of gastric mucosal cancer with special reference to relationship of histological pictures between the mucosal cancer and the cancer-bearing gastric mucosa. Gann Monographs 1961, 52, 109.
9. 9. Jarvi O. and Lauren P. On the role of heterotopias of the intestinal epithelium in the pathogenesis of gastric cancer. Acta Pathol. Microbiol. Scand. 1951, 29, 26.
10. 10. Lauren P. The two histologic main types of gastric carcinoma: diffuse and the so-called intestinal type carcinoma, Acta Pathol. Microbiol. Scand. 1965, 64, 31.
11. 11. Brenes F. and Correa P. Pathology of gastric cancer. Surg. Onc. Clinics North America 1993, 2, 347-370.
12. 12. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Sem. in Onc. 1984, 12, 2.
13. 13. Dent D., Madden M. and Price S. Controlled trials and the R1/R2 controversy in the management of gastric carcinoma. Surg. One. Clinics of North America 1993, 2, 433-441.
14. 14. Okusa T., Nakane Y., Boku T., Takada H., Yamamura M., Hioki K. and Yamamoto M. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surg. Gynecol. Obstet. 1990, 170, 488.
15. 15. Maruyama, K. Results of surgery correlated with staging. In Cancer of the Stomach, pp. 145-163 (eds Preece, P. E., Cusehieri, A. and Wellwood, J. M.) Grune & Stratton, London, 1986.
16. 16. Jatzko G. R., Lisborg P. H., Denk H., Klimpfinger M. and Stettner H. M. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer 1995, 76, 1302-1312.
17. 17. Okajima K. Surgical treatment of gastric cancer with special reference to lymph node removal. Acta Med. Okayama 1977, 31, 369.
18. 18. Noguchi Y., Imada T., Matsumoto A., Coit D. G. and Brennan M. F. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989, 64, 2053.
19. 19. Douglass, H. O. Jr. Gastric cancer. In General Surgery, pp. 133-164 (eds Ritchie, W. P., Steele, G. and Dean, R. H.) Lippincott, Philadelphia, 1995.
20. 20. Bozzetti F., Bonfanti G., Bufalino R., Menotti V., Persano S., Andreola S., Doci R. and Gennari L. Adequacy of margins in resection in gastrectomy for cancer. Ann. Surg. 1982, 196, 685-690.
21. 21. Papachristou D. N., Agnanti N. and D'Agostino H. etal.,. Histologically positive esophageal margin in the surgical treatment of gastric cancer. Amer. J. Surg. 1980, 139, 711-713.
22. 22. Korenaga T., Okamura H., Baba H., Saito A. and Sugimachi K. Results of resection of gastric cancer extending to adjacent organs. Br. J. Surg. 1988, 75, 12-15.
23. 23. Wanebo H. J., Kennedy B. J., Chmiel J., Steele G. Jr., Winchester D. and Osteen R. Cancer of the stomach, a patient care study by the American College of Surgeons. Ann. Surg. 1993, 218, 583-592.
24. 24. Roder, J. D., Boettcher, K. and Siewert, J. R. Results of the German Gastric Cancer Study, multivariate analysis of potentially prognostic factors in 1654 resected patients. In International Gastric Cancer Congress, pp. 47-54 (eds Nishi, M., Sugano, H. and Takahashi, T.) Monduzzi Editore, Bologna, Italy, 1995.
25. 25. Japanese Research Society for Gastric Cancer. Treatment results of gastric carcinoma in Japan, 39th Report of nationwide registry in 199?-1982. 1995.
26. 26. Pacelli F., Doglietto G. B., Bellantone R., Alfieri S., Sgadari ? and Crucitti F. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br. J. Surg. 1993, 80, 1153-1156.
27. 27. Volpe C. M., Koo J., Miloro S. M., Driscoll D. L., Nava H. R. and Douglass H. O. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. JACS 1995, 181, 56-64.
28. 28. Baba H., Machara Y., Takeuchi H., Inutsuka S., Okuyama T., Adachi Y., Akazawa K. and Sugimachi K. Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery 1995, 117, 165-169.
29. 29. Siewert J. R., Bottcher K., Roder J. D., Busch R., Hermanek P. and Meyer H. J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br. J. Surg. 1993, 80, 1015-1018.
30. 30. Bonenkamp J. J., Songun I., Hermans J., Sasako M., Welvaart K., Plukker J. T. M., van Elk P., Obertob H., Gouma D. J., Taat C. W., van Lanschot J., Meyer S., de Graaf P. W., von Meyenfeldt M. F., Tilanus H. and van de Velde C. J. H. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345, 745-748.
31. 31. Cuschieri A., Fayers P., Fielding J., Craven J., Bancewicz J., Joypaul V. an Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996, 347, 995-999.
32. 32. Dent D. M., Madden M. V. and Price S. K. Randomized comparison study of R2 gastrectomy for gastric carcinoma. Br. J. Surg. 1988, 75, 110-112.
33. 33. Wu C., Hsieh M., Lo S., Wang L., Hsu W., Lui W., Huang M. and P'eng F. Morbidity and mortality after radical gastrectomy for patients with carcinoma of the stomach. JACS 1995, 181, 26-32.
34. 34. Douglass H. O. Jr. The R2 dissection in the treatment of gastric malignancy. Sur. Onc. Cl. NA 1993, 2, 413-431.
35. 35. Bunt A. M. G., Hermans J., Smit V. T. H. B. M., van de Velde C. J. H., Fleuren G. J. and Bruijn J. A. Surgical? Pathologic-stage migration confounds comparison of gastric cancer survival rates between Japan and western countries. J Cl. Onc. 1995, 13, 19-25.
36. 36. Roder J. D., Bonenkamp J. J., Craven J., van de Velde C. J. H., Sasako M., Bottcher K. and Stein H. J. Lymphadenectomy for gastric cancer in clinical trials: update. World Journal Surg. 1995, 19, 546-553.
37. 37. Cady B., Rossi R. L., Silverman M. L., Piccione W. and Heck T. A. Gastric adenocarcinoma: a disease in transition. Arch. Surg. 1989, 124, 303-308.
38. 38. Wanebo H. J., Kennedy B. J., Winchester D. P., Fremgen A. and Stewart A. K. Castries carcinoma: does lymph node dissection alter survival? JACS 1996, 183, 616-624.
39. 39. Minsky B. D. The role of radiation therapy in gastric cancer. Seminars in Oncology 1996, 23, 390-396.
40. 40. Kelsen D. P. Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology 1996, 23, 379-389.
41. 41. Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982, 49, 1116-1122.
42. 42. Engstrom P. F., Lavin P. T., Douglass H. O. Jr. and Brunner K. W. Postoperative adjuvant 5-fluorouracil plus methyl CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275). Cancer 1985, 55, 1868-1873.
43. 43. Higgins G. A., Amadeo J. H., Smith D. E., Humphrey E., W. and Keehu R. J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group report. Cancer 1983, 52, 1105-1112.
44. 44. Estape J., Grau J., Alcobendas F., Curto J., Daniels M., Vinolas N. and Pera C. Mitomycin C as an adjuvant treatment to resected gastric cancer: a 20-year follow-up. Ann. Surg. 1991, 00, 219-221.
45. 45. Carrato A., Diaz-Rubio E., Medrano J. et al. Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C and tegafur plus uracil, starting within the first week after surgery, for gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 1995, 14, 198.
46. 46. Krook J. E., O'Connell M. J., Wieand H. S., Beart R. W. Jr., Leigh J. E., Kugler J. W., Foley J. F., Pfeifle D. M. and Twito D. I. A prospective, randomized evaluation of intensive course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991, 67, 2454-2458.
47. 47. Allum W. H., Hallissey M. T. and Kelly K. A. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1989, 1, 571-574.
48. 48. Nakajima T., Takahashi T., Takagi K., Kuno K. and Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 1984, 2, 1366-1371.
49. 49. Gagliano R., McCracken J. and Chen T. Adjuvant chemotherapy with FAM in gastric cancer: a SWOG study. Proc. Am. Soc. Clin. Oncol. 1983, 2, 114.
50. 50. Coombes R. C., Schein P. S., Chilvers C. E., Wils J., Beretta G., Bliss J. M., Rutten A., Amadori D., Cortes-Funes H., Villar-Gumalt A., McArdle C., Rauschecker H. F., Boven E., Vassilopoulos P., Welvaart K., Pinto Ferreira E., Wiig J., Gisselsbrecht C., Rougier P. and Woods E. M. A. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J. Clin. Oncol. 1990, 8, 1362-1369.
51. 51. Hallissey M. T., Dunn J. A., Ward L. C. and Allum W. H. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994, 343, 1309-1312.
52. 52. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Cancer, English edn. Kanehara, Tokyo, 1995.
53. 53. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J. Surg. 1981, 11, 127-139.
54. 54. Progress in gastric cancer research. In eds Siewert, J. R. and Roder, J. D. Monduzzi Editore, Bologna, 1997.
55. 55. Noguchi Y., Imada T., Matsumoto A. et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989, 64, 2053.